fbpx
Search
Close this search box.

Bi-Weekly Newsletter 1-14-2022

newsletter1.14.22

Our 2021 in Numbers!

2021 went by in a flash, but not before our team hit some really great numbers! Before we get too far into 2022, we wanted to take a moment to reflect back on all the milestones we hit in the past year and share some of our favorite numbers with you. Thank you for continuing to support InVivo Biosystems and include us in your research journey. We can’t wait to see what 2022 has in store for us! Learn more

Featured Findings:

How Probiotics are Being Used to Combat COVID-19

Beyond research into vaccines and traditional therapeutics, the medical community is exploring other ways of helping to prevent, and reduce, symptoms of COVID-19. One promising supplement is a common probiotic. In this article we will discuss the studies that have been conducted, their findings, and answer the question: who could benefit from taking probiotics?

Read more

 

A Look Back: Sharing Some of our Customer’s Successes

As we head into 2022, we are reflecting on the exciting projects we’ve been involved with over the past few years, and the engrossing conversations we’ve had. To hear full-length versions of these conversations check out our 17 Minutes of Science podcast page.

Read more

 

The In (vitro, vivo, silico)s and Outs of Research

Experiments fall into three categories – in vivo, in vitro, and in silico studies, and all of them have a different, but important role in research. This article will give a brief definition of each category and an overview of their research applications.

Read more

 

The Discrepancy Between Sexes: Clinical Models & Clinical Trials

Pharmaceutical drugs go through a rigorous process that tests their safety and efficacy before gaining FDA approval and being put on the commercial market. Traditionally, preclinical trials utilize mammalian models before clinical trials are performed (mammals are considered the gold standard of trials). But are these trials serving everyone? This article will discuss the pervasive inequality between the male and female sexes in drug development and what can be done about it.

Read More

 

What is the new Split hygromycin method? How does it differ from MosSCI? How can we use it to help you?

In 2020 a new method of inserting transgenes into the genome of C. elegans was introduced to the field, and was quickly adopted by InVivo Biosystems. In this article we will discuss the new Split hygromycin method, how it differs from the traditional MosSCI method, and what benefits this new method has both for us in the InVivo Biosystems lab, and for our customers.

Read more

Industry News:

P.S.

We want to feature YOU and your research on 17 Minutes of Science. We love enabling your research and think the work you are doing is awesome. So awesome in fact that we want to share your story – from how you got into science and your favorite mentor, to your most recent achievements and how you are giving back to the scientific community.

If you are interested in joining us, you can fill out this short form and we will reach out to you!

About The Author

InVivo Biosystems

InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome editing, InVivo Biosystems creates custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in early-stage development of new compounds.

Share this articles

Facebook
Twitter
Pinterest
LinkedIn
InVivo Biosystems

About the Author:

Connect with us